Inflation Reduction Act: A Game Changer for Cardiovascular Therapies Access

By Staff Writer

September 29, 2023

First 10 Drugs Announced for Medicare Price Negotiation

On August 29, 2023, the Biden-Harris administration revealed the first 10 drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA). Five of these drugs treat cardiovascular conditions such as atrial fibrillation and heart failure. This is a significant step towards improving access to lifesaving therapies for cardiovascular conditions that affect millions of older US residents.

The rising prevalence of cardiovascular and metabolic diseases in the elderly (65 years and above) has been a significant factor in the development of new pharmaceutical treatments. This has also caused a shift in standard care practices, with the adoption of newer, costlier brand-name drugs in place of older, more affordable generics.

For example, the replacement of warfarin with direct oral anticoagulants (DOACs) for preventing stroke in atrial fibrillation patients is discussed. Warfarin comes at a mere $4 per month, whereas DOACs can cost between $378 to $566 monthly. This price difference has resulted in a nearly 17-fold surge in Medicare’s annual expenditure on oral anticoagulation therapy, from an estimated $440 million in 2011 to a whopping $7.4 billion in 2019.

This narrative is continued by examining the evolution of medical treatment guidelines for patients suffering from heart failure with reduced ejection fraction (HFrEF). The previous standard treatment comprised three affordable generic drugs: a β-blocker, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and a mineralocorticoid receptor antagonist. The current standard, however, includes sacubitril/valsartan and a sodium-glucose cotransporter-2 inhibitor. The cost disparity is significant. While the former regimen could cost as low as $10 a month, the current standard-of-care regimen can exceed $1200 a month.

Implications for Patients and Manufacturers

The IRA plans to address the issue of high medication costs by negotiating prices with drug manufacturers. They anticipate this negotiation will save the government $100 billion from 2026 to 2031. The lower negotiated price will also reduce out-of-pocket costs for patients. Additionally, the IRA will mandate all Part D plans to cover drugs with negotiated prices, improving access to these medications.

Reference url

Recent Posts

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.